Selective Depletion of Regulatory T Cell Subsets by Docetaxel Treatment in Patients with Nonsmall Cell Lung Cancer
Regulatory T (Treg) cells are potent suppressors that maintain immune homeostasis. Accumulation of Treg can inhibit effective immune responses in cancer patients, leading to tumor development and progression. Despite direct cytotoxicity, several chemotherapeutic drugs have been reported to deplete T...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2014/286170 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849400416510410752 |
|---|---|
| author | Jie-Yao Li Xiu-Fang Duan Li-Ping Wang Yu-Jie Xu Lan Huang Teng-Fei Zhang Jin-Yan Liu Feng Li Zhen Zhang Dong-Li Yue Fei Wang Bin Zhang Yi Zhang |
| author_facet | Jie-Yao Li Xiu-Fang Duan Li-Ping Wang Yu-Jie Xu Lan Huang Teng-Fei Zhang Jin-Yan Liu Feng Li Zhen Zhang Dong-Li Yue Fei Wang Bin Zhang Yi Zhang |
| author_sort | Jie-Yao Li |
| collection | DOAJ |
| description | Regulatory T (Treg) cells are potent suppressors that maintain immune homeostasis. Accumulation of Treg can inhibit effective immune responses in cancer patients, leading to tumor development and progression. Despite direct cytotoxicity, several chemotherapeutic drugs have been reported to deplete Treg cells for better prognosis for cancer patients. Treg cells are a heterogenous population with at least three different subsets, nonsuppressive, resting, and activated Treg cells. However, the characteristics of Treg cell subsets in lung cancer patients and how chemotherapy affects Treg cells remain elusive. In this study, we first analyzed Treg cell subsets in peripheral blood samples from 40 nonsmall cell lung cancer (NSCLC) patients and 20 healthy donors. Treg cells, specifically activated Treg cell subset, significantly increased in patients with NSCLC. Compared to nonsuppressive Treg cells, activated Treg cells expressed higher level of CD39 and predominantly produced inhibitory cytokines. In vitro assay showed that docetaxel reduced all three subsets of Treg cells. More importantly, we found docetaxel-based chemotherapy significantly decreased all three Treg subsets after 4 cycles of treatment in 17 NSCLC patients. Taken together, this study revealed dynamic changes of various Treg cell subsets in NSCLC patients before and after chemotherapy, providing activated Treg cells as a potential target for chemotherapy. |
| format | Article |
| id | doaj-art-87fb1ca87f9943e8954a92330854e270 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-87fb1ca87f9943e8954a92330854e2702025-08-20T03:38:05ZengWileyJournal of Immunology Research2314-88612314-71562014-01-01201410.1155/2014/286170286170Selective Depletion of Regulatory T Cell Subsets by Docetaxel Treatment in Patients with Nonsmall Cell Lung CancerJie-Yao Li0Xiu-Fang Duan1Li-Ping Wang2Yu-Jie Xu3Lan Huang4Teng-Fei Zhang5Jin-Yan Liu6Feng Li7Zhen Zhang8Dong-Li Yue9Fei Wang10Bin Zhang11Yi Zhang12Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, ChinaDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, ChinaDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, ChinaDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, ChinaBiotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, ChinaBiotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, ChinaDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, ChinaBiotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, ChinaBiotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, ChinaDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, ChinaDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, ChinaDepartment of Medicine-Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USADepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, ChinaRegulatory T (Treg) cells are potent suppressors that maintain immune homeostasis. Accumulation of Treg can inhibit effective immune responses in cancer patients, leading to tumor development and progression. Despite direct cytotoxicity, several chemotherapeutic drugs have been reported to deplete Treg cells for better prognosis for cancer patients. Treg cells are a heterogenous population with at least three different subsets, nonsuppressive, resting, and activated Treg cells. However, the characteristics of Treg cell subsets in lung cancer patients and how chemotherapy affects Treg cells remain elusive. In this study, we first analyzed Treg cell subsets in peripheral blood samples from 40 nonsmall cell lung cancer (NSCLC) patients and 20 healthy donors. Treg cells, specifically activated Treg cell subset, significantly increased in patients with NSCLC. Compared to nonsuppressive Treg cells, activated Treg cells expressed higher level of CD39 and predominantly produced inhibitory cytokines. In vitro assay showed that docetaxel reduced all three subsets of Treg cells. More importantly, we found docetaxel-based chemotherapy significantly decreased all three Treg subsets after 4 cycles of treatment in 17 NSCLC patients. Taken together, this study revealed dynamic changes of various Treg cell subsets in NSCLC patients before and after chemotherapy, providing activated Treg cells as a potential target for chemotherapy.http://dx.doi.org/10.1155/2014/286170 |
| spellingShingle | Jie-Yao Li Xiu-Fang Duan Li-Ping Wang Yu-Jie Xu Lan Huang Teng-Fei Zhang Jin-Yan Liu Feng Li Zhen Zhang Dong-Li Yue Fei Wang Bin Zhang Yi Zhang Selective Depletion of Regulatory T Cell Subsets by Docetaxel Treatment in Patients with Nonsmall Cell Lung Cancer Journal of Immunology Research |
| title | Selective Depletion of Regulatory T Cell Subsets by Docetaxel Treatment in Patients with Nonsmall Cell Lung Cancer |
| title_full | Selective Depletion of Regulatory T Cell Subsets by Docetaxel Treatment in Patients with Nonsmall Cell Lung Cancer |
| title_fullStr | Selective Depletion of Regulatory T Cell Subsets by Docetaxel Treatment in Patients with Nonsmall Cell Lung Cancer |
| title_full_unstemmed | Selective Depletion of Regulatory T Cell Subsets by Docetaxel Treatment in Patients with Nonsmall Cell Lung Cancer |
| title_short | Selective Depletion of Regulatory T Cell Subsets by Docetaxel Treatment in Patients with Nonsmall Cell Lung Cancer |
| title_sort | selective depletion of regulatory t cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer |
| url | http://dx.doi.org/10.1155/2014/286170 |
| work_keys_str_mv | AT jieyaoli selectivedepletionofregulatorytcellsubsetsbydocetaxeltreatmentinpatientswithnonsmallcelllungcancer AT xiufangduan selectivedepletionofregulatorytcellsubsetsbydocetaxeltreatmentinpatientswithnonsmallcelllungcancer AT lipingwang selectivedepletionofregulatorytcellsubsetsbydocetaxeltreatmentinpatientswithnonsmallcelllungcancer AT yujiexu selectivedepletionofregulatorytcellsubsetsbydocetaxeltreatmentinpatientswithnonsmallcelllungcancer AT lanhuang selectivedepletionofregulatorytcellsubsetsbydocetaxeltreatmentinpatientswithnonsmallcelllungcancer AT tengfeizhang selectivedepletionofregulatorytcellsubsetsbydocetaxeltreatmentinpatientswithnonsmallcelllungcancer AT jinyanliu selectivedepletionofregulatorytcellsubsetsbydocetaxeltreatmentinpatientswithnonsmallcelllungcancer AT fengli selectivedepletionofregulatorytcellsubsetsbydocetaxeltreatmentinpatientswithnonsmallcelllungcancer AT zhenzhang selectivedepletionofregulatorytcellsubsetsbydocetaxeltreatmentinpatientswithnonsmallcelllungcancer AT dongliyue selectivedepletionofregulatorytcellsubsetsbydocetaxeltreatmentinpatientswithnonsmallcelllungcancer AT feiwang selectivedepletionofregulatorytcellsubsetsbydocetaxeltreatmentinpatientswithnonsmallcelllungcancer AT binzhang selectivedepletionofregulatorytcellsubsetsbydocetaxeltreatmentinpatientswithnonsmallcelllungcancer AT yizhang selectivedepletionofregulatorytcellsubsetsbydocetaxeltreatmentinpatientswithnonsmallcelllungcancer |